Image

Middle East and Africa Ataxia Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Apr 2022
  • MEA
  • 350 Pages
  • No of Tables: 233
  • No of Figures: 48

Middle East and Africa Ataxia Market, By Type (Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), Product (Treatment and Diagnosis), Dosage Form (Solid, Liquids, and Others), Route of Administration (Oral, Parenteral, and Others), Patient Type (Adult, Child, and Geriatric), End User (Hospital, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2029.

Middle East and Africa Ataxia Market

Middle East and Africa Ataxia Market Analysis and Insights 

The growing prevalence of ataxia disease has enhanced the market's demand. The rising healthcare expenditure for better health services also contributes to the market's growth. During this crucial period, the major market players are highly focused on product launches and product approvals. In addition, the government and regulatory bodies are supporting market players by product approval due to surging emergence.

The Middle East and Africa ataxia market is growing in the forecast year due to the rise in market players and the availability of advanced products. Along with this, manufacturers are engaged in R&D activity for launching novel products in the market. The increasing research in the field of ataxia therapeutics and the rise in consumption of alcohol and drugs usage are expected to boost the market growth further. However, the difficulty in diagnosing the disease and the lack of genetic testing facilities in some developing countries might hamper the growth of the Middle East and Africa ataxia market in the forecast period.

The rising healthcare expenditure and strategic initiatives by market players may give the market opportunities to enhance the treatment. However, some stringent rules and regulations associated with the approval of drugs and products and product recall from various companies are expected to challenge the market growth.

Middle East and Africa ataxia market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.6% in the forecast period of 2022 to 2029 and is expected to reach USD 518.38 thousand by 2029 from USD 377.38 thousand in 2021.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020

Quantitative Units

Revenue in USD thousand, Pricing in USD

Segments Covered

By Type (Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), Product (Treatment and Diagnosis), Dosage Form (Solid, Liquids, and Others), Route of Administration (Oral, Parenteral, and Others), Patient Type (Adult, Child, and Geriatric), End User (Hospital, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)

Countries Covered

South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait, the Rest of the Middle East and Africa

Market Players Covered

Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Cipla Inc., among others

Market Definition

Ataxia is a term for a group of disorders that affect coordination, balance, and speech. Anybody part can be affected, but people with ataxia often have difficulties with balance, walking, speaking, swallowing, and tasks requiring a high degree of control, such as writing, eating, and vision. The exact symptoms and their severity vary depending on the type of ataxia a person has.

Ataxia usually results from damage to a part of the brain called the cerebellum, but it can also be caused by damage to other parts of the nervous system. This damage can be part of an underlying condition such as MS (multiple sclerosis) or can be caused by a head injury, lack of oxygen to the brain, or long-term, excessive alcohol consumption. Hereditary ataxia is caused by a faulty gene passed on by family members who may or may not be affected.

Middle East and Africa Ataxia Market Dynamics

Drivers

  • Rapid research in the field of ataxia therapeutics

There is an enormous range of risk factors being reported for ataxia. Hence, to reduce the risk factors and symptoms associated with it, various research is going on in ataxia treatments. Some government funding has also been initiated to treat various types of ataxia in the market. Various rapid research in the field of ataxia therapeutics may help drive the market over the forecasted period and anticipate the major growth in the research and development for the same.

  • Rise in alcohol and drug usage

Rising alcohol and drug usage can lead to vitamin B-12, vitamin E, and thiamine deficiency. The lack of these nutrients in the body is considered to be a major cause of ataxia. A shortage of vitamin E in the body can lead to neurological problems, such as difficulty coordinating movements (ataxia) and speech (dysarthria), loss of reflexes in the legs (lower limb areflexia), and a loss of sensation in the extremities (peripheral neuropathy) this then leads to the various types ataxia. The rising number of people and youth consuming excessive alcohol and drugs also increases the chance of being affected by various types of ataxia. This is expected to act as a driver for the growth of the Middle East and Africa ataxia market.

Opportunities

  • Rising healthcare expenditure

Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, the government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for ataxia as the disorder has been highly prevalent in recent years.

Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for the ataxia market in the forecast period of 2022-2029.

Restraints/Challenges

However, the difficulty in diagnosing the disease and lack of genetic testing facilities in some developing countries will impede the growth rate of the Middle East and Africa ataxia market. Additionally, stringent rules and regulations will further challenge the forecast period's market.

This Middle East and Africa ataxia market report provide details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa ataxia market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.

Post COVID-19 Impact on Middle East and Africa Ataxia Market

COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence, various treatment drugs have widely increased in the world's population. Thus, the pandemic has positively affected this market.

Recent Development

  • In November 2021, Sanofi announced that the company had completed its acquisition with Kadmon. This has helped the company expand its product portfolio and increase its revenue through various generic medicine products

Middle East and Africa Market Scope

The Middle East and Africa ataxia market is segmented into type, product, dosage form, route of administration, patient type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

  • Spinocerebellar Ataxias
  • Ataxia-Telangiectasia
  • Episodic Ataxia
  • Others (Multiple System Atrophy (MSA))

On the basis of type, the Middle East and Africa ataxia market is segmented into spinocerebellar ataxias, ataxia-telangiectasia, episodic ataxia, and others (multiple system atrophy (MSA)).

Product

  • Diagnosis
  • Treatment

On the basis of product, the Middle East and Africa ataxia market is segmented into treatment and diagnosis.

Dosage Form

  • Solid
  • Liquids
  • Others

On the basis of dosage form, the Middle East and Africa ataxia market is segmented into solid, liquids, and others.

.Route Of Administration

  • Oral     
  • Parenteral
  • Others

On the basis of route of administration, the Middle East and Africa ataxia market is segmented into oral, parenteral, and others.

Patient Type

  • Adult
  • Child
  • Geriatric

On the basis of patient type, the Middle East and Africa ataxia market is segmented into adult, child, and geriatric.

End User

  • Hospital
  • Clinics
  • Home Healthcare
  • Others

On the basis of end users, the Middle East and Africa ataxia market is segmented into hospital, clinics, home healthcare, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Others

On the basis of distribution channel, the Middle East and Africa ataxia market is segmented into direct tender, retail sales, and others.

Middle East and Africa Ataxia Market Regional Analysis/Insights     

The Middle East and Africa ataxia market is analyzed and market size insights and trends are provided by country, type, product, dosage form, route of administration, patient type, end user, and distribution channel.

Some of the countries covered in this region are South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait, the rest of the Middle East and Africa. South Africa is expected to dominate the Middle East and Africa ataxia market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of ataxia in the region, and rapid research development is boosting the market.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and African brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Ataxia Market Share Analysis

Middle East and Africa ataxia market competitive landscape provide details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Middle East and Africa ataxia market.

Some of the major players operating in the Middle East and Africa ataxia market are Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Cipla Inc., among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Middle East and Africa vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding of the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1  MIDDLE EAST & AFRICA ATAXIA MARKET: PIPELINE ANALYSIS

TABLE 2  MIDDLE EAST & AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 3  MIDDLE EAST & AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4  MIDDLE EAST & AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 5  MIDDLE EAST & AFRICA ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 6  MIDDLE EAST & AFRICA EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7  MIDDLE EAST & AFRICA OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 8  MIDDLE EAST & AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 9  MIDDLE EAST & AFRICA TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 10  MIDDLE EAST & AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 11  MIDDLE EAST & AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 12  MIDDLE EAST & AFRICA STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 13  MIDDLE EAST & AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 14  MIDDLE EAST & AFRICA ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 15  MIDDLE EAST & AFRICA NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 16  MIDDLE EAST & AFRICA ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 17  MIDDLE EAST & AFRICA ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 18  MIDDLE EAST & AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 19  MIDDLE EAST & AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 20  MIDDLE EAST & AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 21  MIDDLE EAST & AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 22  MIDDLE EAST & AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23  MIDDLE EAST & AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 24  MIDDLE EAST & AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 25  MIDDLE EAST & AFRICA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 26  MIDDLE EAST & AFRICA SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 27  MIDDLE EAST & AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 28  MIDDLE EAST & AFRICA LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 29  MIDDLE EAST & AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 30  MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31  MIDDLE EAST & AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 32  MIDDLE EAST & AFRICA ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33  MIDDLE EAST & AFRICA PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 34  MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35  MIDDLE EAST & AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 36  MIDDLE EAST & AFRICA ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37  MIDDLE EAST & AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 38  MIDDLE EAST & AFRICA CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 39  MIDDLE EAST & AFRICA GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40  MIDDLE EAST & AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 41  MIDDLE EAST & AFRICA HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42  MIDDLE EAST & AFRICA CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 43  MIDDLE EAST & AFRICA HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 44  MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 45  MIDDLE EAST & AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 46  MIDDLE EAST & AFRICA DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 47  MIDDLE EAST & AFRICA RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 48  MIDDLE EAST & AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 49  MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 50  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 51  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 52  MIDDLE EAST AND AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 53  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 54  MIDDLE EAST AND AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 55  MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 56  MIDDLE EAST AND AFRICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 57  MIDDLE EAST AND AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 58  MIDDLE EAST AND AFRICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 59  MIDDLE EAST AND AFRICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 60  MIDDLE EAST AND AFRICA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 61  MIDDLE EAST AND AFRICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 62  MIDDLE EAST AND AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 63  MIDDLE EAST AND AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 64  MIDDLE EAST AND AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 65  MIDDLE EAST AND AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 66  MIDDLE EAST AND AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 67  MIDDLE EAST AND AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 68  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 69  MIDDLE EAST AND AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 70  MIDDLE EAST AND AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 71  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 72  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 73  MIDDLE EAST AND AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 74  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 75  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 76  MIDDLE EAST AND AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 77  SOUTH AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 78  SOUTH AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 79  SOUTH AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 80  SOUTH AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 81  SOUTH AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 82  SOUTH AFRICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 83  SOUTH AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 84  SOUTH AFRICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 85  SOUTH AFRICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 86  SOUTH AFRICA ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 87  SOUTH AFRICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 88  SOUTH AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 89  SOUTH AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 90  SOUTH AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 91  SOUTH AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 92  SOUTH AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 93  SOUTH AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 94  SOUTH AFRICA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 95  SOUTH AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 96  SOUTH AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 97  SOUTH AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 98  SOUTH AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 99  SOUTH AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 100  SOUTH AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 101  SOUTH AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 102  SOUTH AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 103  SAUDI ARABIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 104  SAUDI ARABIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 105  SAUDI ARABIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 106  SAUDI ARABIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 107  SAUDI ARABIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 108  SAUDI ARABIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 109  SAUDI ARABIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 110  SAUDI ARABIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 111  SAUDI ARABIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 112  SAUDI ARABIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 113  SAUDI ARABIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 114  SAUDI ARABIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 115  SAUDI ARABIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 116  SAUDI ARABIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 117  SAUDI ARABIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 118  SAUDI ARABIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 119  SAUDI ARABIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 120  SAUDI ARABIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 121  SAUDI ARABIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 122  SAUDI ARABIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 123  SAUDI ARABIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 124  SAUDI ARABIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 125  SAUDI ARABIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 126  SAUDI ARABIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 127  SAUDI ARABIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 128  SAUDI ARABIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 129  U.A.E ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 130  U.A.E SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 131  U.A.E ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 132  U.A.E TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 133  U.A.E PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 134  U.A.E STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 135  U.A.E GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 136  U.A.E ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 137  U.A.E NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 138  U.A.E ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 139  U.A.E ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 140  U.A.E ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 141  U.A.E SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 142  U.A.E LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 143  U.A.E SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 144  U.A.E DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 145  U.A.E IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 146  U.A.E IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 147  U.A.E SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 148  U.A.E LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 149  U.A.E ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 150  U.A.E ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 151  U.A.E ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 152  U.A.E ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 153  U.A.E ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 154  U.A.E RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 155  ISRAEL ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 156  ISRAEL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 157  ISRAEL ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 158  ISRAEL TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 159  ISRAEL PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 160  ISRAEL STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 161  ISRAEL GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 162  ISRAEL ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 163  ISRAEL NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 164  ISRAEL ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 165  ISRAEL ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 166  ISRAEL ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 167  ISRAEL SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 168  ISRAEL LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 169  ISRAEL SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 170  ISRAEL DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 171  ISRAEL IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 172  ISRAEL IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 173  ISRAEL SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 174  ISRAEL LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 175  ISRAEL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 176  ISRAEL ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 177  ISRAEL ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 178  ISRAEL ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 179  ISRAEL ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 180  ISRAEL RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 181  EGYPT ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 182  EGYPT SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 183  EGYPT ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 184  EGYPT TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 185  EGYPT PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 186  EGYPT STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 187  EGYPT GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 188  EGYPT ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 189  EGYPT NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 190  EGYPT ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 191  EGYPT ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 192  EGYPT ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 193  EGYPT SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 194  EGYPT LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 195  EGYPT SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 196  EGYPT DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 197  EGYPT IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 198  EGYPT IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 199  EGYPT SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 200  EGYPT LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 201  EGYPT ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 202  EGYPT ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 203  EGYPT ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 204  EGYPT ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 205  EGYPT ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 206  EGYPT RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 207  KUWAIT ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 208  KUWAIT SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 209  KUWAIT ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 210  KUWAIT TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 211  KUWAIT PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 212  KUWAIT STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 213  KUWAIT GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 214  KUWAIT ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 215  KUWAIT NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 216  KUWAIT ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 217  KUWAIT ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 218  KUWAIT ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 219  KUWAIT SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 220  KUWAIT LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 221  KUWAIT SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 222  KUWAIT DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 223  KUWAIT IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 224  KUWAIT IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 225  KUWAIT SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 226  KUWAIT LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 227  KUWAIT ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 228  KUWAIT ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 229  KUWAIT ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 230  KUWAIT ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 231  KUWAIT ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 232  KUWAIT RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 233  REST OF MIDDLE EAST AND AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

Middle East and Africa Ataxia Market is growing with a CAGR of 4.6% by 2029
Middle East and Africa Ataxia Market is expected to reach USD 518.38 thousand by 2029
The major players operating in the Middle East and Africa ataxia market are Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Cipla Inc., among others.
Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, the government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for ataxia as the disorder has been highly prevalent in recent years.